
The availability of zzso human zzso zzso 2 zzso has enabled clinical trials to test its in zzso zzso We report here the zzso effects of 7 consecutive days of zzso treatment given to 25 patients with cancer in a clinical Phase I zzso zzso blood zzso obtained from patients following therapy with zzso had enhanced zzso responses to zzso and enhanced direct zzso activity on zzso target zzso This zzso activity was further zzso by the addition of zzso during the zzso release zzso Fresh peripheral blood zzso from some patients who had just completed treatment at the higher zzso dose levels were able to kill both the natural zzso zzso cell line and fresh tumor cells while zzso samples and peripheral blood zzso from healthy controls were zzso This zzso activity was best detected when zzso was present in the in zzso zzso zzso These results demonstrate that the administration of zzso to patients with cancer zzso a population of zzso cells able to directly destroy natural zzso target cells, when zzso in the presence of zzso 

